Zealand Pharma — Juni 2023
-
Jeg glemt vist nok at sige god morgen tidligere men så tager vi lige den nu - God morgen på endnu en flot solskins dag!
-
Zealand Pharma: Data shows nearly 19% weight loss https://www.proinvestor.com/boards/113406
-
SMADK - Det var aboslut interessante citater fra Carinne Brouillon.
-
-
AstraZeneca har droppe udviklingen af AZD0186, som var en oral GLP-1. Det er anden GLP-1 kandidat, som AZ har droppe og de lukker nu GLP-1 programmet ned. https://www.fiercebiotech.com/biotech/astrazeneca-drops-another-glp-1-after-phase-1-data-busts-market-beating-diabetes-hopes
-
Her er en artikel, hvor læge og Boehringer Ingelheim’s corporate vice president og chef for cardiometabolisk medicin, Waheed Jamal, udtaler sig om den læringskurve som BI har været igennem i tolkningen af studiet. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients
-
“What we'll take forward into the phase 3 is that we will have a much lower titration—probably somewhere around every four weeks as opposed to every two weeks that we've had in phase 2,” he said. “We will allow plenty of flexible titration throughout the trial in phase 3.”
Boehringer is now in discussions with regulators about launching a phase 3 trial, Jamal said, though he didn’t reveal an anticipated timeline. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-
-
Tak ApS invest. Dette link duer. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients
-
Lægger alle de relevant links ind her de kommende dage: https://www.proinvestor.com/boards/113406/
-
Medwatch:
"Zealand Pharma og den tyske partner Boehringer Ingelheim har serveret yderligere data fra et fase 2-studie med fedmekandidaten Survodutid BI 456906.
De peger på endnu mere udtalte vægttab, når man bliver på behandlingen i længere tid, og de viser også, at Zealand og Boehringer Ingelheim ikke har set udviklingen stoppe efter de 46 uger, som studiet løb".
Zealand Pharma og partner serverer flere data fra lovende fedmekandidat
De peger bl.a. på endnu mere udtalte vægttab, når man bliver på behandlingen i længere tid.
(medwatch.dk)
-
YPE - Jeg kan godt følge din logik men skal jeg tage de strategisk briller på så ser jeg noget andet her som også er interessant. Hvis jeg var BI's topledelse så ville jeg seriøst se på at komme med et opkøbsbud på ZP. De vil pludselig kunne købe sig til en hel "fedme portefølje" her. Det som de kommer til at betale i milepæle og royalty i fremtiden ville kunne betale en god del af opkøbet. De vil også kun få en delvis finansiering ved frasalg af andre projekter.
-
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP8396 and were well-sustained over six weeks of observation
In development as an alternative non-incretin peptide therapy for the potential management of overweight and obesity
A 16-week multiple ascending dose (MAD) study of ZP8396 has been initiated -
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions https://www.proinvestor.com/boards/113432
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind